Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance
Tuesday, March 24, 2020PCA has joined with 12 other key health organisations* to endorse interim consensus guidance, Managing haematology and oncology patients during the COVID-19 pandemic, published in the Medical Journal of Australia
Pending further evidence, the guidance summarises the clinical presentation and diagnosis of COVID-19 disease, provides factors to consider when managing patients with cancer, and discusses risk factors for severe COVID-19 disease. Possible actions for clinicians managing patients with cancer are suggested, and are phased according to the presence or absence of community transmission and disruption to normal healthcare provision.
Read the full article here: Managing haematology and oncology patients during the COVID-19 pandemic
The interim guidance was endorsed by the following organisations*:
- Australasian Leukaemia and Lymphoma Group
- Australasian Lung Cancer Trials Group
- Australian and New Zealand Children’s Haematology/Oncology Group
- Australia and New Zealand Society of Palliative Medicine
- Bone Marrow Transplantation Society of Australia and New Zealand
- Cancer Society of New Zealand
- Clinical Oncology Society of Australia
- Haematology Society of Australia and New Zealand
- National Centre for Infections in Cancer
- New Zealand Cancer Control Agency
- New Zealand Society for Oncology
- Palliative Care Australia